News & Events

C-Path Launches Rare Disease Clinical Outcome Assessment Consortium

The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseases TUCSON, Ariz., January 13, 2022 — Critical Path Institute (C-Path) today announced the launch of the Rare Disease Clinical Outcome Assessment (COA) Consortium, a public-private partnership focused on optimizing COA selection during medical product development for […]

C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium

  TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of […]

C-Path Promotes Nick King and Emily Turner to Executive Directors

TUCSON, Ariz., November 10, 2021 — Critical Path Institute (C-Path) today announced it has promoted Nicholas King, M.S., as Executive Director of its Predictive Safety Testing Consortium (PSTC) and Emily Turner, Ph.D., as Executive Director of the Huntington’s Disease Regulatory Science Consortium (HD-RSC). “Nick and Emily have been incredible assets to our organization and will […]

C-Path and Cure Mito Announce Data Sharing Agreement to Support Treatment Development For Leigh Syndrome and Mitochondrial Disease

TUCSON, Ariz., November 9, 2021 — Critical Path Institute (C-Path) and Cure Mito Foundation (Cure Mito) today announced a joint collaboration to significantly promote data sharing and accelerate Leigh syndrome and other rare mitochondrial disease data incorporation into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Leigh syndrome, also known as Leigh disease, is […]